AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model
Cyril Quivoron(Inserm), Virginie Penard‐Lacronique(Université Paris-Sud), Hua Yang(China Pharmaceutical University), Stéphane de Botton(Université Paris-Saclay), Hyeryun Kim(Agios Pharmaceuticals (United States)), Jeremy Travins(Agios Pharmaceuticals (United States)), Christophe Willekens(Université Paris-Saclay), Kim Straley(Agios Pharmaceuticals (United States)), Dongwei Zhu(Agios Pharmaceuticals (United States)), Véronique Saada(Université Paris-Saclay), Katharine Yen(Agios Pharmaceuticals (United States)), Paule Opolon(Institut Gustave Roussy), Olivier Bernard(Université de Poitiers), Mélanie Polrot(Institut Gustave Roussy), Sam Agresta(Agios Pharmaceuticals (United States)), Muriel D. David(Inserm), Olivia Bawa(Université Paris-Saclay), Yue Chen(Cedars-Sinai Medical Center), Jean‐Baptiste Micol(Université Paris-Saclay)
Cited by 19
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Substrate and Functional Diversity of Lysine Acetylation Revealed by a Proteomics Survey
|Molecular Cell|2006|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Acetylation Is Indispensable for p53 Activation
|Cell|2008|828